

Regimen Reference Order – LYMP – BEGEV

ARIA: LYMP - [BEGEV]

Planned Course: Every 21 days for 4 cycles

Indication for Use: Hodgkin Lymphoma, Relapsed/Refractory

CVAD: At Provider's Discretion (VESICANT INVOLVED)

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ Contact Hematologist if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP – BEGEV

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Day 1		
predniSONE	100 mg	Orally once in the morning with food (Self-administered at home)
metoclopramide	10 mg	Orally 30 minutes pre-chemotherapy
vinorelbine	20 mg/m ²	IV in normal saline 50 mL over 6 to 10 minutes by gravity infusion <i>Slower or faster administration causes vein irritation</i>
normal saline	125 mL	IV over 15 minutes *Nursing Alert: This volume is to be administered after standard flush
gemcitabine	800 mg/m ²	IV in normal saline 250 mL over 30 minutes
Days 2 and 3		
predniSONE	100 mg	Orally once daily in the morning with food (Self-administered at home)
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
bendamustine	90 mg/m ²	IV in normal saline 500 mL over 1 hour
normal saline	100 mL	IV over 12 minutes

Day 4		
predniSONE	100 mg	Orally once in the morning with food (Self-administered at home)
metoclopramide	10 mg	Orally 30 minutes pre-chemotherapy
gemcitabine	800 mg/m ²	IV in normal saline 250 mL over 30 minutes

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
pegfilgrastim (brand name specific) (See Filgrastim Clinical Guide)	6 mg	Subcutaneous once on Day 6 <i>*Alert: pegfilgrastim to be given as a single dose once per chemotherapy cycle no sooner than 24 hours after chemotherapy</i>
valACYclovir	500 mg	Orally once daily
sulfamethoxazole-trimethoprim	800/160 mg	Orally once daily on Mondays, Wednesdays and Fridays
dexamethasone	8 mg	Orally once on Days 5
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Ensure patient receives pegfilgrastim supply if patient is self-administering at home
- predniSONE is a cancer therapy in this treatment regimen. Remind patient to take predniSONE at home
- Instruct patient to continue taking anti-emetic(s) and supportive care medications at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- valACYclovir is prescribed for herpes zoster (shingles) prophylaxis. Herpes zoster prophylaxis should be considered in patients with:
 - A history of shingles or recurrent cold sores
 - Treatment with bendamustine in the relapsed setting
- sulfamethoxazole-trimethoprim is prescribed for *Pneumocystis jirovecii* pneumonia prophylaxis
- allopurinol is not routinely prescribed with bendamustine containing regimens as the use of allopurinol given concomitantly with bendamustine can increase the risk of serious skin reactions